Article

The Crossroad between Intellectual Property and Clinical Trials: Balancing Incentives for Innovation with Access to Healthcare

Hmna Ahmad[1], Ifrah Shabbir[1*], Irfana Iqbal[2], Muhammad Masoom Akhtar[3]

[1] Dr. Ikram-ul-Haq Institute of Industrial Biotechnology (IIIB), Government College University Lahore (GCUL) Katchery Road, Lahore 54000, Pakistan; ifrahshabbir0303@gail.com
[2] College of Life Science and Engineering, Southwest University of Science and Technology, Mianyang Sichuan, 621053, China; Irfkhn@gmail.com
[3] Faculty of Pharmacy, Hamdard University Islamabad Campus, 4 Park Link Road, Park Road, Islamabad, Pakistan; m.masoom@hamdard.edu.pk
* Correspondence: ifrahshabbir0303@gmail.com

Abstract: The interplay between intellectual property rights (IPRs) and clinical trials presents a complex challenge in the realm of healthcare innovation. This paper examines the critical role of IPRs, particularly patents, in incentivizing pharmaceutical research and development while simultaneously addressing their implications for access to essential medicines, especially in low- and middle-income countries (LMICs). We explore the phases of clinical trials that underpin medical advancements and highlight the significant financial and temporal investments required for drug development. The discussion also delves into the tensions created by monopolistic pricing, data exclusivity, and evergreening practices that hinder equitable access to healthcare. Through a review of international agreements like the TRIPS Agreement and case studies on HIV/AIDS, hepatitis C treatments, and COVID-19 vaccines, we illustrate the urgent need for policy reforms and alternative incentive models, including prize funds, patent pools, and tiered pricing strategies. Our findings underscore the necessity for a balanced approach that fosters innovation while ensuring that life-saving medications are accessible to all populations. Ultimately, this paper calls for collaborative efforts among governments, international organizations, and the private sector to create an equitable healthcare landscape that prioritizes public health needs without stifling innovation.

Keywords: intellectual property rights; health; clinical trials; pharmaceutical; licensing; patents

Citation: Hmna Ahmad, Ifrah Shabbir, Irfana Iqbal, Muhammad Masoom Akhtar. 2023. The Crossroad between Intellectual Property and Clinical Trials: Balancing Incentives for Innovation with Access to Healthcare. *Trends in Intellectual Property Research 2*,12-18. https://doi.org/10.69971/tipr.1.2.2023.16

1. Introduction

The relationship between intellectual property (IP) protection, on the one hand, and the availability of medicines, on the other hand, has become a burning topic in contemporary healthcare, particularly, in the pharmaceutical sector. It gives temporal monopoly power in compliance with patent-based IP systems facilitates innovation as firms may invest in research and development as well as carrying out expensive clinical trials of novel medicines (Hettinger 1989). However, the exclusivity of such rights tends to lead to high costs of drugs, which limit access to affordable medical care as well as increase the worries about global health equity, especially in poor nations (Kesselheim et al. 2007).

Clinical studies play one of the central roles in promoting new drugs, and the costs are indeed high. The organizations that venture into such trials expect to have their financial investments pay off based on the monopoly of the commercial sector presented by the patents and other Intellectual property rights (Light and Lexchin 2012). These safeguards is critical to pharmaceutical companies, as it cushions against the high financial risks of launching new medications. However, monopolistic dominance has an effect of increasing the prices of valuable medicines, and this limits the access to the needy populations. This power was particularly evident during the global epidemic of HIV/AIDS where expensive antiretroviral medications added to escalate health disasters in the developing world (Hubbard and Love 2004).

The IP issues and the access to healthcare are especially topical within the context of financially catastrophic medical expenditures, when individuals or families are forced to spend a significant part of their income on healthcare costs, often due to the excessive cost of IP-protected drugs (Jung and Kwon 2015). The monopolistic nature of pharmaceutical patents often increases the price of life-saving treatments and makes them unaffordable to many people. Sell (2003) underlines that the fact that IP rights and the massive spending on healthcare are correlated explains why the current IP system is somewhat unethical, as it is focused on profit rather than fair access. The global outbreak of COVID-19 has highlighted the conflict between the IP rights and global

health goals. The process of producing vaccines was accelerated by the assurance of global health crisis monopolistic IP protection (Morten and Moss 2020). Most of the portions of the vaccines were bought by rich nations and many of the developing nations were left short of the necessary supplies making the global difference in receiving access to medicines a priority of the IP rights.

Considering such difficulties, the legal flexibility to allow countries to grant compulsory licenses is sought by such measures as The Doha Declaration on the TRIPS Agreement and Public Health in order to allow developing cost-effective generic equivalents to patented drugs in case of a national health emergency (Hubbard and Love 2004). This strategy has a potential compromise of promoting innovation and affordability of vital medicines in times of crisis. Despite the essential nature of IP protections in enhancing innovation and in contributing towards the creation of new medicines, can also provide a barrier to access to healthcare among financially vulnerable groups of the population. The current research of the long-term tension between innovation and access, explains that there is a need to continue changes in policies helping to offer universal access to medicines without compromising the innovative forces of the pharmaceutical industry.

2. Intellectual property rights in healthcare

In pharmaceuticals and healthcare center, patents are the significant form of intellectual property rights, where they provide exclusive rights to companies up to 20 years. Such exclusivity facilitates innovation by allowing companies to recover the substantial costs of research and development (R&D), and clinical research (Hettinger 1989, Light and Lexchin 2012). The monopoly created by patents permit pharmaceutical companies to control pricing, which can limit the availability of medicines in developing regions (Kesselheim et al. 2007, Jung and Kwon 2015). Data exclusivity assist as an intellectual property right protects clinical trial data by prohibiting competitor approach to generic drug approvals.

This situation restricts the availability of lower-cost generics that could improve access to affordable medicine (Jung and Kwon 2015). Data exclusivity often surpasses patent duration, lengthens market exclusivity for the original drug, retards competition, and maintains high costs of drugs (Kapczynski et al. 2012).

Monopoly pricing granted by IPRs results in inherent medicine being unreasonable for many populations, particularly in developing countries. Limited accessibility of low-cost generic medicines remains a major hurdle impartial drug availability (Hubbard and Love 2004). The HIV/AIDS crisis emphasize how strong intellectual property protection can limit access to life-saving drugs. In 1990s high cost of patented antiretroviral drugs restricted access in developing countries, reducing treatment coverage and raising deaths (Jung and Kwon 2015, Kesselheim et al. 2007). The TRIPS Agreement of World Trade Organization (WTO) contains compulsory licensing that authorize governments to set aside patent exclusivity in health emergencies. This mechanism enables the production of affordable patented medicines and enhances the availability of drug alternatives (Hubbard and Love 2004). Brazil and South Africa's experience with compulsory licensing for HIV/AIDS drugs and illustrates how intellectual property rights adaptability can protect public health. Overall, compulsory licensing is a critical policy tool for confirming of availability of essential drugs in developing countries (Jung and Kwon 2015; Light and Lexchin 2012).

Intellectual property rights in healthcare have accelerate global health Inequality, particularly in developing regions. Well developed countries can afford costly patented medicine, while low-income countries lack sufficient access. This inequality emphasizes the importance of balanced IP frameworks in medical treatments between developed and under-developed countries (Hubbard and Love2004, Morten and Moss 2020). COVID-19 revealed global inequalities, developed countries secured bulk of COVID vaccine through IP frameworks, while developing countries experienced limited availability of vaccine (Morten and Moss2020). By sustaining worldwide benchmarks for IP protection, TRIPS Agreement provides a guideline for public health emergencies, allowing countries the utilization of compulsory licenses and alternative mechanisms to improve the availability of essential medicines to public (Jung and Kwon 2015). The Doha Declaration confirmed the right of countries to emphasize population health during health disasters such as HIV/AIDS and COVID-19 (Hubbard and Love 2004).

Pharmaceutical industries implementing "evergreening" strategies by making minor modification to current medications to increase patent life. Such approaches delay generic competition and sustain high drug prices (Kapczynski et al. 2012The collection of overlaying patents on a single medicine, known as patent thickets, create hinderance in generic access and maintain high prices for essential drugs (Maggiolino 2011). The equilibrium between intellectual property rights and population well-being remains a challenging matter among policymakers and worldwide health institutions (Morten and Moss 2020, Kapczynski et al. 2012). During public health crises flexible IP frameworks allow compulsory licensing and related tools to ensure that innovation advantages are available to public worldwide (Jung and Kwon 2015).

3. Clinical Trials: The Foundation of Medical Innovation

Clinical trials are the backbone of modern medicine and plays a critical role in development of new drugs and health technologies. Clinical trials are organized into 4 phases, each phase is important for evaluating safety, efficacy, and proper use (Jung and Kwon 2015).

- **Phase I:** This phase often includes a small number of healthy individuals or patients. This phase mainly focuses of confirming the safety of the drugs. Researchers examine the how drugs interact inside the body with various organs, pharmacokinetics properties, and the optimal dosage of the drug (Royle2017).
- **Phase II:** In this phase, the prepared drug is tested in a larger number of individuals, typically individuals suffered with relevant disease. This mainly focus on therapeutic efficacy, also deal with the safety of the drugs.
- **Phase III:** This phase of clinical trials is largest and expensive includes hundreds to thousands of patients, examine the effectiveness of particular drugs and also test their side effects, and compare it with standard or placebo therapies. It is crucial in achieving approval from the agencies such as the FDA (Jung and Kwon 2015).

- **Phase IV:** This phase, referred as post-marketing surveillance, this phase starts once a drug receives approval for public use. It involves long-term investigations to evaluate its effectiveness in larger populations and identify any unexpected adverse effects of the drug (Royle 2017).

Clinical trials play an important role in transforming research discoveries into valuable patient benefits, forming a disciplined and robust framework that supports progress in modern healthcare innovation (Jung and Kwon 2015). However, the high cost and extensive duration associated with clinical trials are the major hinderance in pharmaceutical innovation and drug development. Approximately $1–2 billion cost is required to introduce new drug into market and requires 10-15 years to reach commercialization (Light and Lexchin 2012). Multiple factors contribute to these high costs as presented in Figure 1:

- Pre-clinical research expenses: Before the start of clinical testing, extensive laboratory testing and animal studies are performed to demonstrate the initial safety and biological compatibility of drug.
- Clinical trial progression: Expenses of the drug increase due to successful advancement of drug through the successive trial of drug on large population (Jung and Kwon 2015).
- Regulatory advancement: Completing strict regulatory standards established by the agencies FDA and EMA significantly contributes to rise of development time and expenses particularly during Phase III involving large population (Royle 2017).
- High failure rate: One of the major contributors to high cost is the high failure rate of drug in market, 90% of drugs failing to achieve approval during clinical trials, resulting in significant economic losses (Jung and Kwon 2015, Light and Lexchin 2012).

Intellectual property rights are vital in enabling pharmaceutical companies to recoup the investments link with drug development (Kapczynski et al. 2012). Patent protection and data exclusivity provide innovators a short period to attain financial returns before the generics enter in market (Light and Lexchin 2012). IP rights play significant role in shaping the design, conduct, and outcomes of clinical trials, by shaping data-sharing practices.

- **Investment motivation:** Strong IP protections, such as patents and data exclusivity motivate pharmaceutical companies to invest in costly clinical trials. Without guaranteed exclusivity pharmaceutical companies would be less willing in investment of new drug development (Kapczynski et al. 2012).
- **Design consideration:** IP regimes can also affect the structure of trial, pharmaceutical companies favoring the designs that are most attractive and enhance marketing of drug. Without guaranteed exclusivity firms would be not willing to invest billions on clinical trials in new drug development (Jung and Kwon 2015).
- **Data sharing and access to trial results**: Access to data: IP protections facilitate the financial recovery; IP regime also restrict access to trial data. Pharmaceutical companies may restrict access to data to protect competitive advantages, especially during patent protection (Royle2017).

Data exclusivity policies protect patents from competitors from using original data to obtain approval for generic medicines even after patent expiration. This can delay limit to affordable generics and limit access to life saving medicine. (Hubbard and Love 2004).



Figure 1. Multiple factors contribute to high cost

4. The intersection of IP and access to health care

Intellectual property (IP) policies, with an emphasis on patents, intends to foster innovation by granting inventors with exclusive rights for their innovations over a defined period. Under the pharmaceutical industry, these initiatives support companies in recouping substantial research and development (R&D) outlays. Nevertheless, IP can limit access to some of the required medics particularly in the low-income economies (LMICs) where affordability is a big impediment. Critical drug patents like HIV/AIDS

and cancer will give rise to monopolies and inflate prices that are not within reach of many (Ford et al. 2004). Drug producers rationalize this type of excessive prices by the fact that it is needed to offset the research and developement that may take billions of dollars in the form of medicine. Yet, this is a pretext that has the propensity of blocking these important treatments to underserved groups (Reichman 2009). There is some inconsistency in promoting innovation and ensuring large access to medicines. On the one hand, pharmaceutical companies claim that in the absence of intellectual property not many people would be motivated to invest in expensive and risky research and development activities. Conversely, the opponents indicate that the rights of patent monopolies tend to result into extravagant prices that are becoming unaffordable to the majority of the populace who reside in LMICs (Outterson 2009). It is one of the key problems of the global health policy to find a balance between the goals of compensating in-novation and affordable life-saving medicines which could be accessible to everyone. Among the solutions to this issue, one can mention the government-approved licensing where the governments are permitted to grant a license to produce generic versions of the patented medicines in case of the emergency situation within the context of the pandemic. Whereas this is approved under the international agreements like the TRIPS, pharmaceutical firms and even individual high-income states have objected to this (Abbott 2002). IP laws have the most influential effect on access to healthcare in the LMICs, where the problem of access to highly demanded medicines is a significant concern. The international trade treaties which are trans-national in nature of the pharmaceutical patents normally increase this challenge. The monopolies that result in the patenting of vital medicines in the LMICs can increase the costs of the medicines to unaffordable levels and only ensure that a vital treatment is accessible to virtually all groups of people at risk (Ford et al. 2004). Indicatively, HIV/AIDS management through the use of antiretroviral drugs was inaccessible in a number of LMICs until the international pressure which saw the creation of generic drugs (Baker 2008). The cycle repeats itself with the invention of new therapies to cure such diseases as hepatitis C and cancer where the access is often blocked out by patent monopolies. TRIPS program is an agreement designed by the World Trade Organization (WTO) in 1995, which encompasses internationally the standards of protection of intellectual property, which comprise of the patents in the pharmaceutical industry. Though TRIPS requires every member to implement the minimum IP standards, there are flexibilities that are provided, such as obligatory licensing and parallel importation that could be employed by the nations to enhance access to the required drugs (Correa 2000). All these flexibilities were renewed in the 2001 Doha Declaration on the TRIPS Agreement and Public Health in which it stated that the protection of intellectual property must not impair the effort of nations to protect public health (Abbott 2002). It is evident, that TRIP must be revised and executed in defense of the rights of the WTO members to protect the health of the people and to broaden the access to medicines of the board. Although the Doha Declaration was a major move towards health equity in the world, it has remained a point of concern whether this initiative and other trade agreements under TRIPS provide health equity to the global community or the interests of the big corporations (Baker 2008). It has numerous concrete examples that testify to the complexity of the relationships between IP rights and the right to healthcare. In part of the cases, IP has enabled innovation, although in part cases it has limited access to necessary drugs.

- **HIV Crisis in South Africa**

During 1990s, South Africa was faced with a massive HIV epidemic with millions of people in need of antiretroviral (ARV) therapy. However, the high prices of patented ARV drugs put them above the affordability of the majority of residents. In response to this, the government adopted laws that allowed production of generic substitutes, based on obligatory licensing provisions under TRIPS. Though the pharmaceutical companies vehemently opposed this, the pressure exerted by the rest of the world finally saw cheap corpora-tions being provided, and many lives are saved (Ford et al. 2004).

- **Hepatitis C treatments**

The treatment of hepatitis C has raised some similar de-bates with the advent of specific antiviral (DAAs) in later years. These drugs, which are of high prices due to patent rights, have limited accessibility in most of the re-source restricted nations. In retaliation, some countries have made pro-duction or importation of generic products a mandatory license, to the chagrin of pharmaceutical companies (Reichman 2009). This case highlights the ongoing conflict between encouraging innovation and ensuring the accessibility of critical treatments.

- **COVID-19 vaccine patents**

In the COVID-19 pandemic, the focus on IP rights and medicine availability was reoriented, in particular, when it comes to the allocation of vaccines. Most LMICs faced challenges in obtaining adequate doses due to patent issues and supply chain challenges even as most high-income states had obtained vaccines in large amounts beforehand. Pharmaceutical companies and even some of the wealthiest nations opposed such initiatives to have a short-term waiver of TRIPS on COVID-19 technologies but the issue is being discussed (Hoen 2021). These cases underscore the perpetual challenge of having to balance IP enforcement and the need to have access to essential medicines, especially in LMICs.

5. Potential solutions and Policy Proposals

The presence of the IP systems and especially patents create monopolies that helps to fuel the increase in prices of drugs and restrict the access to most necessary medicines particularly in developing nations. In response to these shortcomings, other incentive systems have been proposed to help medical innovation and enhance access to and affordability of necessary medicine.

One such alternative is prize funds where the innovators do not get a patent exclusivity but cash prizes (Love 2007). Such prizes could be financed by international organization to encourage people to create new drugs. An example is that such prizes would enable the cure of malaria or tuberculosis diseases, which are prevalent among the LMICs, but are less commercially pursued. This model isolates the costs of R&D and the cost of the drugs so that new drugs can be distributed cheaply (Outterson 2009).

The patent pools bring different stakeholders into a single pool; some of them are pharmaceutical companies, research institutions and other government agencies (Ford et al. 2004). This strategy endorses cooperation in research and development and might also assist the low-price medications. The Medicines Patent Pool is a good example and was formed to help increase access to HIV treatment in developing nations through encouraging the licensing of patents to generic regimes (Baker 2008). The received result of MPP has triggered the desire to apply this model to other illnesses like COVID-19 and Hepatitis C.

The open access systems promote the open distribution of research and scientific results, inspiring more to develop a new drug (Hoen 2021). This method became of great interest in the COVID-19 pandemic, with researchers and governments focusing on the open dissemination of vaccine and other vaccine related technology. Open COVID Pledge, which was promoted to companies to release their IP as free during the pandemic, emphasizes the role of open access in enhancing the innovation to allow people to have access to life saving treatments.

There are specific policy interventions required between the protection of intellectual property and the necessity to have affordable medicines. Some of the major suggestions on how this balance can be attained include the following:

- **Reducing patent exclusivity**

One of the possible resolutions is to shorten the term of patent exclusivity of necessary life-saving drugs. The change would enable earlier introduction of generic drugs, which would lead to lower cost and better access (Reichman 2009). The use of shorter exclusivity of medicines that the public health authorities consider essential so that affordability of basic treatments can be more quickly accessible.

- **Promoting voluntary licensing**

Voluntary licensing agreements, allow owners of patents to license their drugs as a condition to receive royalty payments, this reduces the price of the drugs and incentives are offered to innovators (Outterson 2009). The international organization and government could persuade pharmaceutical firms to finance such agreements and particularly drugs that are essential to the health of the population. This has worked well in the case of HIV drugs, and has possibilities in the therapeutic fields.

- **Increasing the application of compulsory licensing**

By enforcing a compulsory licensing, the governments may allow the manufacturing of generic varieties of patented medications without the consent of patent holders in cases of common health epidemics Abbott 2002 Although this provision is acknowledged under the TRIPS Agreement, there are governments facing pressure by the developed economies and pharmaceutical companies limiting its application. Enhancing the support of this provision in the world, especially by the World Trade Organization (WTO), would help to enhance the access to essential drugs in low- and middle-income countries (Correa 2000).



Figure 2. A clear flow chart showing the intesection of Intellectual Property (IP) laws and access to health advantages. The flow chart highlights important trials in balancing the requirement to incentivize innovation through IP protection while ensuring affordable access to vital medications, particularly in developed and middle-income countries (LMICs).

- **Tiered pricing models**

Tiered, also known as differential pricing is the practice of having different prices on a condition of same medicines depending on the economic position of a nation or the economic capacity of the population (Baker 2008). Drugs being patented would be charged high prices to high-income nations and lower to LMICs. The model assists firms to recuperate the research and development expenses besides expanding access to vital medicines. The global organizations, such as the WHO, have promoted the expanded use of graduated pricing in order to minimize healthcare inequalities.

5.1. The Role of Governments and International Organizations

The governments and global bodies are crucial in the development of regulatory mechanisms that will encourage innovation and access to drugs. These ends can be achieved with various important mechanisms:

- **IP management regulatory frameworks.**

Governments can balance the needs of innovators with the needs of the community through regulatory frameworks. As an example, the concept of patent linkage, which requires authorizations of generic drugs to be developed in the expiration of a specific patent to be granted could be adjusted to accelerate the process of introducing essential generic drugs (Ford et al. 2004). Secondly, it is possible to enforce the lawmakers to open up the regulatory avenues to allow the early introduction of generics in cases of a national health emergency as a measure of ensuring rapid access to life-saving drugs.

- **Accountability of the international organizations**

International institutions such as WTO, WHO and WIPO are at the forefront of the global debate on the intellectual property and healthcare accessibility. The Doha Declaration on the TRIPS Agreement and Public Health underlined that IP regulations need to be construed to promote the public health objectives (Abbott 2002). Enforcement of international cooperation and flexibility in the structure of IP legislation can help such organizations ensure that IP protection does not hinder access to life-saving medications.

- **Innovation encouraged on neglected diseases**

The neglected diseases that are mostly experienced by people at LMICs do not receive adequate focus by pharmaceutical companies because of weak market incentive. The gap can be overcome by governments and global organizations by investing in the neglected diseases research and development or offering subsidies and tax breaks to encourage investment in the private-sector (Baker 2008). The example of such effective collaborations is offered by such a program as the Drugs for Neglected Diseases Initiative (DNDi). It focuses on developing medicines against malaria, tuberculosis, and Chagas disease that would have been neglected under the conventional profit-making provisions.

6. Conclusions

The free balance in the connection of IP rights and healthcare demands that the incentive to innovation should not hinder access to the necessary drugs. IP framework plays a role in encouraging R&D, they may also lead to high drug prices that makes the drugs inaccessible especially in LMICs. Prize funds and patent pools are good solution, which would support innovation without creating financial burden on patients. To overcome these inequities, policymakers ought to consider such adaptable policies like voluntary and compulsory licensing. Agencies like WTO, WHO and WIPO with international interests have a significant contribution to make towards the regulation structure that balances gains and innovations. In the end, increased cooperation and fair policymaking will help to make sure that the medical innovations do not just benefit the developed populations. The focal point of attaining global health equity is balancing of innovation.

References

Abbott, Frederick M. 2002. The Doha Declaration on the TRIPS Agreement and public health: lighting a dark corner at the WTO. *Journal of International Economic Law*5: 469-505. https://ssrn.com/abstract=1493725.

Baker, Brook K. 2008. Processes and issues for improving access to medicines: willingness and ability to utilize TRIPS flexibilities in non-producing countries. https://www.iprsonline.org/resources/docs/Baker_TRIPS_Flex.pdf.

Correa, Carlos Maria. 2000. *Intellectual property rights, the WTO, and developing countries: The TRIPS Agreement and policy options*. Zed Books, New York: USA.

Ford, Nathan, Wilson David, Bunjumnong Onanong, Schoen-Angerer Tido von. 2004. The role of civil society in protecting public health over commercial interests: lessons from Thailand. *The Lancet* 363: 560-563. https://doi.org/10.1016/s0140-6736(04)15545-1 .

Hettinger, Edwin C. 1989. Justifying intellectual property rights. *Philosophy & Public Affairs* 18:31-52.

Hoen, Erwin T. 2021. A critical review of the TRIPS Waiver proposal for COVID-19 vaccines. *Global Health Journal* 3: 1-9.

Hubbard, Tim, Love James. 2004. A new trade framework for global healthcare R&D. *PLoS Biology* 2: e52. https://doi.org/10.1371/journal.pbio.0020052 .

Jung, Youn, Kwon Soonman.2015. The effects of intellectual property rights on access to medicines and catastrophic expenditure. *International Journal of Health Services* 17: 295-318. https://doi.org/10.1177/0020731415584560 .

Kapczynski, Am., Chaifetz Samantha, Benkler Yochai, Zachary Katz. Y. 2012. Addressing global health inequities: An open licensing approach for university innovations. *Berkeley Technology Law Journal* 24: 947-977. https://ssrn.com/abstract=1323527 .

Kesselheim, Aaron S, Avorn Jerry, Sarpatwari Ameet. 2007. The high cost of prescription drugs in the United States: origins and prospects for reform. *Journal of American Medical Association* 316: 858-871. https://doi.org/10.1001/jama.2016.11237 .

Light, Donald W, Lexchin Joel R. 2012. Pharmaceutical R&D—what do we get for all that money? *British Medical Journal* 344: e4348. https://doi.org/10.1136/bmj.e4348 .

Love, James. 2007. Measures to enhance access to medical technologies, and new methods of stimulating innovation in medicines. *Health Affairs* 26: 792-802.

Maggiolino, M. 2011. Pharmaceutical patents: overprotection's detrimental effects on market structure and innovation. *Journal of Law and Health* 24: 85-108.

Morten, Chris, Moss Alex. 2020. Could a patent get in between you and a COVID-19 test? Yes. https://www.theguardian.com/commentisfree/2020/may/20/coronavirus-patents-testing-us-senate .

Outterson, Kevin. 2005. The legal ecology of resistance: The role of patent law in microbial resistance. *Journal of Law, Medicine & Ethics* 33: 588-596.

Outterson, Kevin.2009. The legal ecology of resistance: the role of antibiotic resistance in pharmaceutical innovation. *Cardozo Law Review* 09-48. https://ssrn.com/abstract=1492150 .

Reichman, Jerome H. 2009. Compulsory licensing of patented pharmaceutical inventions: Evaluating the options. *Journal of Law, Medicine & Ethics* 37: 247-263. https://doi.org/10.1111%2Fj.1748-720X.2009.00369.x.

Royle, Jennifer K, Hughes Andrew, Stephenson Laura, Landers Dónal 2021. Technology clinical trials: turning innovation into patient benefit. *Digit Health* 30:7:20552076. https://doi.org/10.1177/20552076211012131.

Sell, Susan K. 2003. *Private power, public law: The globalization of intellectual property rights*. Cambridge University Press.